Press release
Bronchopulmonary Dysplasia Pipeline Analysis 2025: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Therapies, Mechanism of Action, Route of Administration, and Companies by DelveInsight
Bronchopulmonary Dysplasia Pipeline
(Albany, USA) DelveInsight's, "Bronchopulmonary Dysplasia Pipeline Insight 2025" report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Bronchopulmonary Dysplasia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
The Bronchopulmonary Dysplasia Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The Bronchopulmonary Dysplasia pipeline report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Explore our latest breakthroughs in Bronchopulmonary Dysplasia Pipeline. Learn more about our emerging therapies today! @ [https://www.delveinsight.com/sample-request/bronchopulmonary-dysplasia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Key Takeaways from the Bronchopulmonary Dysplasia Pipeline Report
* In September 2024:- EXO Biologics S.A.- Phase I Single Arm, Dose Escalating and Phase II Double Blind, Randomized, Placebo-controlled, Dose Finding Clinical Trial Assessing Safety and Efficacy of Intratracheal Administration of Allogeneic Umbilical Cord Mesenchymal Cells-derived Extracellular Vesicles in Preventing Bronchopulmonary Dysplasia in Extremely Preterm Newborns.
* DelveInsight's Bronchopulmonary Dysplasia pipeline report depicts a robust space with 12+ active players working to develop 12+ pipeline therapies for Bronchopulmonary Dysplasia treatment.
* The leading Bronchopulmonary Dysplasia Companies such as MEDIPOST Co., Ltd., Airway Therapeutics, Oak Hill Bio Ltd, Meridigen Biotech, AyuVis Research, CHIESI Farmaceutici S.p.A., Velvio, Orphanix, Alveolus Bio Inc., Advent Therapeutics, Trimunocor, The Cell Factory BVBA, Windtree Therapeutics, and others.
* Promising Bronchopulmonary Dysplasia Therapies such as Sildenafil, PNEUMOSTEM, OHB-607, and others.
Stay informed about the cutting-edge advancements in Bronchopulmonary Dysplasia Treatments. Download for updates and be a part of the revolution in cancer care @ [https://www.delveinsight.com/sample-request/bronchopulmonary-dysplasia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Emerging Bronchopulmonary Dysplasia Drugs Profile
PNEUMOSTEM: MEDIPOST Co., Ltd
PNEUMOSTEM Registered an allogeneic umbilical cord blood-derived mesenchymal stem cell product, is currently under development for the preventive treatment of Bronchopulmonary Dysplasia (BPD) in premature infants. Currently, Phase 2 clinical trial is ongoing in Korea and PNEUMOSTEM Registered has been Orphan Drug designated by US FDA and EMA. Recently, US FDA granted a Fast Track Designation for PNEUMOSTEM Registered.
AT-100: Airway Therapeutics
AT-100 is a novel recombinant human protein rhSP-D, an engineered version of an endogenous protein that reduces inflammation and infection in the body while modulating the immune response to break the cycle of injury and inflammation. Airway is focused on advancing AT-100 for the prevention of BPD in very preterm born babies and as a therapeutic for seriously ill COVID-19 patients. AT-100's anti-inflammatory and anti-infective properties also make it a potential treatment for other respiratory diseases such as influenza, respiratory syncytial virus (RSV) and inflammatory diseases outside the lung. The FDA and European Medicines Agency have granted AT-100 Orphan Drug Designation.
Learn more about Bronchopulmonary Dysplasia Drugs opportunities @ [https://www.delveinsight.com/sample-request/bronchopulmonary-dysplasia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Bronchopulmonary Dysplasia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical
Bronchopulmonary Dysplasia Products have been categorized under various Molecule types such as
* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy
Discover the latest advancements in Bronchopulmonary Dysplasia Treatment by visiting our website. Stay informed about how we're transforming the future of Oncology @ [https://www.delveinsight.com/sample-request/bronchopulmonary-dysplasia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Scope of the Bronchopulmonary Dysplasia Pipeline Report
* Coverage- Global
* Bronchopulmonary Dysplasia Companies- MEDIPOST Co., Ltd., Airway Therapeutics, Oak Hill Bio Ltd, Meridigen Biotech, AyuVis Research, CHIESI Farmaceutici S.p.A., Velvio, Orphanix, Alveolus Bio Inc., Advent Therapeutics, Trimunocor, The Cell Factory BVBA, Windtree Therapeutics, and others.
* Bronchopulmonary Dysplasia Therapies- Sildenafil, PNEUMOSTEM, OHB-607, and others.
* Bronchopulmonary Dysplasia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Bronchopulmonary Dysplasia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of Bronchopulmonary Dysplasia Pipeline on our website @ [https://www.delveinsight.com/sample-request/bronchopulmonary-dysplasia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Table of Content
* Introduction
* Executive Summary
* Bronchopulmonary Dysplasia: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Bronchopulmonary Dysplasia - DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Drug name: Company name
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* PNEUMOSTEM: MEDIPOST Co., Ltd.
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* AT-100: Airway Therapeutics
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* AVR 48: AyuVis Research
* Drug profiles in the detailed report.....
* Inactive Products
* Bronchopulmonary Dysplasia Key Companies
* Bronchopulmonary Dysplasia Key Products
* Bronchopulmonary Dysplasia- Unmet Needs
* Bronchopulmonary Dysplasia- Market Drivers and Barriers
* Bronchopulmonary Dysplasia- Future Perspectives and Conclusion
* Bronchopulmonary Dysplasia Analyst Views
* Bronchopulmonary Dysplasia Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=bronchopulmonary-dysplasia-pipeline-analysis-2025-clinical-trials-ema-pdma-fda-approvals-medication-therapies-mechanism-of-action-route-of-administration-and-companies-by-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Bronchopulmonary Dysplasia Pipeline Analysis 2025: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Therapies, Mechanism of Action, Route of Administration, and Companies by DelveInsight here
News-ID: 4114121 • Views: …
More Releases from ABNewswire
Stratton Amenities Grows North Texas Presence with Fort Worth Expansion
Expanding beyond Dallas Concierge Services-Ready to serve Fort Worth's booming residential market.
Fort Worth, Texas - Stratton Amenities, a leading provider of luxury amenity and concierge services across the Dallas-Fort Worth metroplex, is excited to announce its official expansion into Fort Worth, reinforcing its commitment to delivering an elevated lifestyle experience through expert Dallas Concierge Services.
Fort Worth's Residential Boom: A Landscape of Opportunity
Fort Worth has recently experienced remarkable growth in its…
Exploring Legal Options After an Injury with a LeFante Personal Injury Lawyer in …
Unexpected injuries can disrupt every part of daily life-from physical well-being to financial stability. Whether from a car accident, a slip-and-fall, or workplace incident, the effects linger long after the initial event. In these situations, knowing there's legal support available makes a major difference. LeFante Law Offices, P.C. is one such resource offering dedicated assistance to those seeking justice and fair compensation. When searching for the right representation, the value…
Hanley Investment Group Brokers $11.3 Million Sale of Pique at Angel Stadium Ret …
ANAHEIM, Calif. - Hanley Investment Group Real Estate Advisors, a nationally recognized real estate brokerage and advisory firm specializing in retail property sales, announced today that the firm arranged the sale of Pique at Angel Stadium, a 100% occupied, 15,710-square-foot multi-tenant retail strip center adjacent to Angel Stadium and within walking distance to the Honda Center and OCVIBE. The sale price was $11.3 million.
Hanley Investment Group's Senior Vice President Lee…
CHZ Lighting Leads the Charge in Smart LED Street Lighting Solutions Across Glob …
Shanghai, China - July 29, 2025 - Shanghai CHZ Lighting Co., Ltd., a pioneer in the LED lighting industry since 2013, continues to revolutionize how cities and municipalities light their streets. As one of China's leading manufacturers and a globally recognized brand in LED street lighting, CHZ Lighting offers not only premium-quality fixtures but also intelligent and energy-efficient lighting solutions tailored for urban transformation.
Engineering the Future of Street Lighting
With more…
More Releases for Bronchopulmonary
Bronchopulmonary Dysplasia (BPD) Epidemiology Market Analysis
Bronchopulmonary Dysplasia (BPD) represents one of the most significant complications of preterm birth, affecting the respiratory system of premature infants and creating substantial healthcare challenges worldwide. The BPD epidemiology market encompasses therapeutic interventions, diagnostic tools, and supportive care technologies designed to address this chronic lung disease affecting neonates. As medical advances continue to improve survival rates among extremely premature infants, the prevalence of BPD has correspondingly increased, driving demand for…
Bronchopulmonary Dysplasia Treatment Market Growth Projections and Trends (2023- …
Bronchopulmonary Dysplasia (BPD) Treatment Market
Global Bronchopulmonary Dysplasia Treatment Market Overview
The global bronchopulmonary dysplasia (BPD) treatment market is poised for significant growth in the coming years. The market was valued at USD X billion in 2023 and is expected to reach USD Y billion by 2030, expanding at a CAGR of Z% from 2024 to 2030. With advancements in neonatal care and increasing awareness about BPD treatment options, the demand for…
Bronchopulmonary Dysplasia Pipeline Therapeutics Assessment Report 2024 (Updated …
DelveInsight's, "Bronchopulmonary Dysplasia Pipeline Insight 2024" report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Bronchopulmonary Dysplasia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Bronchopulmonary Dysplasia Research. Learn more…
Bronchopulmonary Dysplasia Treatment Market Size and Forecast
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- The global Bronchopulmonary Dysplasia Treatment Market is expected to record a CAGR of XX.X% from 2024 to 2031 In 2024, the market size is projected to reach a valuation of USD XX.X Billion. By 2031 the valuation is anticipated to reach USD XX.X Billion.
BDP Market Size And Scope
The global BDP (Butane Diol Propylene) market is witnessing steady growth, fueled by its diverse applications in industries such as…
Bronchopulmonary Dysplasia Market to Reach US$ 445.6 Million by 2034
Market Overview:
The bronchopulmonary dysplasia market reached a value of US$ 269.3 Million in 2023 and expected to reach US$ 445.6 Million by 2034, exhibiting a growth rate (CAGR) of 4.68% during 2024-2034.
The report offers a comprehensive analysis of the bronchopulmonary dysplasia market in the United States, EU5 (including Germany, Spain, Italy, France, and the United Kingdom), and Japan. It covers aspects such as treatment methods, drugs available in the market,…
Bronchopulmonary Dysplasia Treatment Market Size, Players, Revenue Analysis 2023 …
Bronchopulmonary Dysplasia Treatment Market Overview 2023:
The Bronchopulmonary Dysplasia Treatment Market 2023 Report makes available the current and forthcoming technical and financial details of the industry. It is one of the most comprehensive and important additions to the Prudent Markets archive of market research studies. It offers detailed research and analysis of key aspects of the Bronchopulmonary Dysplasia Treatment market. This report explores all the key factors affecting the growth of…
